摘要
目的 探讨克赛引起的不稳定型心绞痛患者血浆血管性血友病因子 (v WF)与内皮素 (ET)的变化。方法 用酶联免疫吸附双抗体夹心法 (ELLSA)与放免法 (RIA)测定不稳定型心绞痛 30例 (1 5例应用克赛治疗 ,1 5例应用硝酸酯类、钙拮抗剂、β受体阻滞剂常规治疗 ) ,观察用药前及 1 w后 v WF、ET水平 ,并进行治疗前后及各组间的统计分析。结果 克赛组治疗前较常规治疗组明显升高 ,治疗后明显下降 ;治疗前克赛组与常规治疗组无显著差异 ,治疗后克赛组下降明显。结论 克赛能够降低不稳定型心绞痛患者血浆中的 v WF、ET水平 ,对血管内皮细胞有保护作用 ,能够减轻血管内皮细胞的损伤。
Objective To explore the change of vWF and ET caused by Enoxaparin of the UA patients. Methods To use Enzyme-Linked Immuno Sorbent Assay (ELLSA) and radioimmunoassay (RIA) to test thirty UA patients, among which fifteen for Enoxaparin group and the others using organic nitrates?calcium antagonists and β-adrenoceptor blocking drugs as the routine treating group. Then respectively do statistical analysis with the level of vWF and ET before treatment ?a week later and of twenty of the normal control group. Results before treatment, the level of the Enoxaparin group is obviously higher than that of the normal control group. After treatment, it is apparently coming down, the descent of which is more evident than the normal control group′s, even though the difference between the Enoxaparin group and the normal control group is little before treatment. Conclusions Enoxaparin is able to reduce the level of vWF and ET in the blood of the UA patients. It can protect vascular endotheliocyte and reduce the trauma.
出处
《中国老年学杂志》
CAS
CSCD
北大核心
2003年第4期233-234,共2页
Chinese Journal of Gerontology
